Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valdone is a bio-enhanced curcumin formulation developed by the Asian Institute of Gastroenterology in India for the treatment of mild to moderate ulcerative colitis. Curcumin, a phytochemical derived from *Curcuma longa*, typically suffers from poor oral bioavailability; Valdone is specifically engineered to improve absorption, allowing for therapeutic effects at lower doses. It functions primarily as an anti-inflammatory and antioxidant agent, with its key mechanism involving the inhibition of nuclear factor-kappa B (NF-κB) signaling pathways. In clinical evaluations, it has been studied as an adjunctive therapy to 5-aminosalicylic acid (5-ASA) to induce clinical and endoscopic remission in patients with ulcerative colitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Valdone.